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The speckle tracking echocardiography (STE) technique allows strain values to be measured in conventional two-dimensional (2D) echocardiographic images processed by dedicated algorithms. In brief, the position of small myocardial footprints (the speckles) generated by ultrasound-myocardial tissue interactions is recognised and monitored throughout the cardiac cycle. 2 STE is now available as a standard tool in the latest generation of echocardiographic machines. The technique preliminarily proved useful in multiple clinical settings, and has progressively been adopted in many echocardiography laboratories, yielding rapid and accurate strain evaluation. 3 The diagnosis of cardiac involvement in systemic sclerosis (SSc) has traditionally relied on the presence of pulmonary hypertension (PHT). Over time, the introduction of more sensitive diagnostic tools has allowed physicians to detect myocardial dysfunction even in asymptomatic SSc patients without PHT. Guerra et al.'s interesting study published in this issue of the European Journal of Preventive Cardiology is in keeping with this paradigm shift. 4 They selected 52 SSc patients without overt cardiac disease and with no evidence of PHT to investigate possible early cardiac involvement. They found that STE-derived strain values in the left and right ventricles were reduced in two-thirds of the patients compared to controls. In contrast, traditional and routinely performed echo parameters, such as ejection fraction or tricuspid annular systolic excursion, did not detect subclinical systolic impairment. After accounting for the vasoactive treatment, even the Doppler-derived diastolic parameters failed to identify any premature alteration. In addition, Guerra et al. found that STE remained significantly associated with SSc diagnosis after adjusting for sex, age and the cardiovascular risk profile, which could influence STE values particularly at the longitudinal level. 5 The strengths of this study include its comprehensive layer-specific STE analysis, and the evaluation of the technique's intra-and inter-observer variability. In addition, the work suggests an early disease-specific echocardiographic phenotype for SSc, which is consistent with previously reported histological and magnetic resonance findings. 6, 7 The global longitudinal strain impairment in the left ventricle occurred in an eccentric pattern: mostly epicardial layers were impaired, while endocardial strain values were similar between SSc and controls, suggesting that STE might serve to characterise a specific SSc-related cardiomyopathy. The possible mechanisms responsible for this typical STE impairment include not only SSc-related vascular lesions leading to myocardial ischaemia, but also patchy myocardial fibrosis. 8, 9 The contribution of an initial elevation in pulmonary vascular resistance or lung alterations should also be taken into account. Indeed, Guerra et al.'s study reported a significant association between subclinical right ventricular systolic dysfunction (by global longitudinal strain) and impaired diffusing capacity of the lungs for carbon monoxide, highlighting STE's ability to reveal the right-ventricle/lung interaction.
In order to transfer these promising data to bedside practice, clinicians and researchers should further concentrate their efforts on defining the clinical relevance of STE changes. In fact, Guerra et al.'s study did not analyse the potential relationship between early cardiac involvement and the occurrence of hard clinical endpoints during follow-up. In this regard, one of the challenges of assessing the prognostic impact of early myocardial impairment, together with the low prevalence of the underlying disease, is the low incidence of cardiac events in the early stages of SSc. A recent pivotal outcome study demonstrated that early right ventricular dysfunction has incremental prognostic value over the other echocardiographic parameters. 10 Although this could depend on the presence and severity of PHT or lung disease, these results further endorse the utility of STE at an early stage of the disease.
Guerra et al.'s study also raises many intriguing questions on SSc clinical management: Should asymptomatic patients with impaired STE be eligible for prompt cardioprotective medical therapy? Could STE be used to monitor the efficacy of such a medical intervention? Is there a subset of patients that needs to be followed-up more closely? What is the prognostic information provided by time-related changes in STE measurements? While these questions await further investigation, Guerra et al.'s study provides important information to help improve the management of SSc patients without overt cardiac involvement.
Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.
